tm logo
SATIVEX
Dead/Abandoned
ABANDONED - AFTER EX PARTE APPEAL

after ex parte appeal

on 23 Jan 2023

Last Applicant/ Owned by

Cambridge CB24 9BZ

GB

Serial Number

79266020 filed on 17th Jul 2019

Registration Number

N/A

Correspondent Address

MICHAEL T OLSEN

WINTHROP & WEINSTINE P A

SUITE 3500

225 SOUTH 6TH STREET

MINNEAPOLIS MN 55402

Filing Basis

1. filing basis filed as 66 a

Disclaimer

NO DATA

SATIVEX

Pharmaceutical and veterinary preparations, namely, for use in treating pain, neuropathic pain, cancer pain, multiple sclerosis, spinal cord injury, bladder dysfunction, peripheral neuropathy, spasticity, cancer and cancer symptoms, perioperative pain, rheumatoid arthritis, inflammatory bowel disease, ulcerative colitis, hypoxic-ischaemic encephalopathy, symptoms of neurogenic disorders, movement Read More

Classification Information


Class [005]
Pharmaceutical Products


Pharmaceutical and veterinary preparations, namely, for use in treating pain, neuropathic pain, cancer pain, multiple sclerosis, spinal cord injury, bladder dysfunction, peripheral neuropathy, spasticity, cancer and cancer symptoms, perioperative pain, rheumatoid arthritis, inflammatory bowel disease, ulcerative colitis, hypoxic-ischaemic encephalopathy, symptoms of neurogenic disorders, movement disorders, essential tremors, psychotic disorders, diseases of the central nervous system, stroke and head injuries, motion sickness and chemically induced sickness, spasticity, psychiatric illnesses, post-traumatic stress disorder, neurodegenerative diseases, metabolic disorders, obesity, obesity associated with Type II Diabetes, bulimia, schizophrenia, Crohn's disease, Alzheimer's disease, bone disorders, inflammatory disorders, sleep and sleep disorders, and drug, alcohol, and nicotine abuse; pharmaceutical preparations for the treatment of neurological conditions and diseases; herbs for medicinal purposes; medicinal herbs; medicinal oils; medicinal infusions, each of the foregoing for use in treating pain, neuropathic pain, cancer pain, multiple sclerosis, spinal cord injury, bladder dysfunction, peripheral neuropathy, spasticity, cancer and cancer symptoms, perioperative pain, rheumatoid arthritis, inflammatory bowel disease, ulcerative colitis, hypoxic-ischaemic encephalopathy, symptoms of neurogenic disorders, movement disorders, essential tremors, psychotic disorders, diseases of the central nervous system, stroke and head injuries, motion sickness and chemically induced sickness, spasticity, psychiatric illnesses, post-traumatic stress disorder, neurodegenerative diseases, metabolic disorders, obesity, obesity associated with Type II Diabetes, bulimia, schizophrenia, Crohn's disease, Alzheimer's disease, bone disorders, inflammatory disorders, sleep and sleep disorders, and drug, alcohol, and nicotine abuse; pure extracts of medicinal plants and herbs for pharmaceutical use; foodstuffs for medicinal purposes; herb teas for medicinal purposes; pharmaceutical preparations for the treatment of pain, neuropathic pain, cancer pain, multiple sclerosis, spinal cord injury, bladder dysfunction, peripheral neuropathy, spasticity, oncology, cancer symptoms, psychiatric illnesses, neurodegenerative diseases and metabolic disorders; plant extracts for pharmaceutical purposes

Mark Details


Serial Number

No 79266020

Mark Type

No Service/Collective Mark

Attorney Docket Number

No

44D Filed

No

44D Current

No

44E filed

No

44E Current

No

66A Filed

Yes

66A Current

Yes

Current Basis

No

No Basis

No

Legal History


Show more

Status DateAction Taken
11th Mar 2024FINAL DECISION TRANSACTION PROCESSED BY IB
12th Feb 2024FINAL DISPOSITION NOTICE SENT TO IB
10th Feb 2024FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
10th Feb 2023ABANDONMENT NOTICE MAILED - AFTER EX PARTE APPEAL
23rd Jan 2023EXPARTE APPEAL TERMINATED
23rd Jan 2023ABANDONMENT - AFTER EX PARTE APPEAL
05th Jan 2023INTERNATIONAL REGISTRATION RENEWED
09th Dec 2022EXPARTE APPEAL DISMISSED - FAILURE TO FILE BRIEF
17th Aug 2022SUBSEQUENT FINAL REFUSAL WRITTEN
17th Aug 2022SUBSEQUENT FINAL EMAILED